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Abstract
Background: Despite intense investment growth and technology development, there is an observed bottleneck in
drug discovery and development over the past decade. NIH started the Molecular Libraries Initiative (MLI) in 2003
to enlarge the pool for potential drug targets, especially from the “undruggable” part of human genome, and
potential drug candidates from much broader types of drug-like small molecules. All results are being made
publicly available in a web portal called PubChem.
Results: In this paper we construct a network from bioassay data in PubChem, apply network biology concepts to
characterize this bioassay network, integrate information from multiple biological databases (e.g. DrugBank, OMIM,
and UniHI), and systematically analyze the potential of bioassay targets being new drug targets in the context of
complex biological networks. We propose a model to quantitatively prioritize this druggability of bioassay targets,
and literature evidence was found to confirm our prioritization of bioassay targets at a roughly 70% accuracy.
Conclusions: Our analysis provide some measures of the value of the MLI data as a resource for both basic
chemical biology research and future therapeutic discovery.
Background
Intense growth in drug development investment in the
past decade has not yet produced significant progress
on the discovery of novel drugs and the validation of
new drug targets: the average number of novel drugs
entering the global market each year has remained
roughly constant (approximately 26), along with only
about 6-7 new drug targets introduced annually [1-3].
Moreover, the success rate of translating new drug can-
didates into US Food and Drug Administration (FDA)-
approved drugs significantly decreased [4], mainly due
to lack of efficacy and discovered adverse drug reactions,
each of which accounts for 30% of late-stage drug fail-
ures in clinical development [5]. The increasing rate of
drug attrition challenges the traditional drug design
paradigm and makes the current “one gene, one drug,
and one disease” assumption [6] questionable.
Under these circumstances, NIH launched the Mole-
cular Libraries Initiative (MLI) in 2003 for identifying
chemical probes to enhance the chemical biology under-
standing of therapeutically interesting genes and path-
ways [7], and for the purpose of expanding availability,
flexibility, and utility of small-molecule bioassay screen-
ing data. The MLI especially focuses on genes in the
“undruggable” part of human genome that has not been
well investigated in private sectors for identifying their
functions and potential therapeutics [7]. The MLI has
also been synthesizing and screening much broader
types of compounds for increasing the diversity of
selecting potential drug candidates in chemical space (i.
e., the set of all possible small organic molecules). All
MLI results are being made freely available to research-
ers in both public and private sectors via a web portal
called PubChem (http://pubchem.ncbi.nlm.nih.gov) [8].
PubChem provides valuable chemical genomics informa-
tion in studying genes, pathways, cells and diseases,
however, these data are noisy, high dimensional, with
large volume, and contain outliers and errors. For
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instance, the activity score, which measure the biological
activity level of screened compounds, are normalized in
many different approaches without a consensus. Hence
PubChem data deserve a careful investigation for the
related research communities.
There are numerous criteria that chemical biologists
might place on an initiative that aims to foster new
paradigms in therapeutic discovery. Some obvious tar-
get-related benchmarks should include whether the
assay priorities focus on the systems that stand a good
chance of being potential druggable targets in their
own right (i.e., share favorable attributes with known
drug targets, and augment current biomedical capabil-
ities). Our assessment of MLI bioassay targets thus
focuses on a variety of their attributes relative to
known drug targets. Given our interest in analyzing
specific relationships with phenotypically interesting
pathways, we choose to focus our target analysis
strictly on target-based assays, whose target proteins
are referred to herein as bioassay targets. As our basis
for contrasting targets, we use target protein interac-
tion profiles in the human PPI network, to evaluate
whether the bioassay target selection was progressing
effectively toward augmenting existing chemical geno-
mics knowledge.
Biological network analysis approaches have gained
popularity for organizing complex biological systems so
that data retrieval, analysis, and visualization can be
highly efficient. It can also reveal important biological
patterns and functions that are deeply hidden in mass
data repository. For instance, Stelzl et al.[9] used the
Y2H system to generate and analyze a human PPI net-
work, and calculated many interesting and critical pat-
terns and characteristics. This was viewed as an
important step toward the complete human protein-pro-
tein interactome. Chaurasia et al.[10,11] built a compre-
hensive web platform - the Unified Human Interactome
database (UniHI, http://www.unihi.org), for querying
and accessing human protein-protein interaction (PPI)
data. The latest update of UniHI includes over 250,000
interactions between 22,300 unique proteins collected
from 14 major PPI sources [11]. Using association data
of approved drugs and drug targets obtained from the
DrugBank database [12,13], Yildirim et al.[2] built a
bipartite network composed FDA-approved drugs and
their drug targets, which was an important step toward
the complete characterization of the global relationship
between protein targets of all drugs and all disease-gene
products in the human protein interactome. Quantita-
tive topological analyses of this drug-target network
revealed that the targets of current drugs are highly
overlapped and new drugs tend to bind previously tar-
geted proteins [2]. In addition, based on disease genes
data from the Online Mendelian Inheritance in Man
(OMIM) database [14], Goh et al.[15] built a bipartite
human disease network, and then generated two biologi-
cally relevant network projections: human disease net-
work and disease gene network. This network-based
approach revealed that genes associated similar disor-
ders are more likely to have interactions between their
products and higher expression profiling similarity
between their transcripts, indicating the existence of dis-
ease-specific functional modules. In this study we use
network-based analysis approaches to integrate Pub-
Chem data and existing research results on drug-target
network [2], human diseasome [15], human protein
interactome [9] for a better understanding of the corre-
lations and interrelationships between disease genes,
genetic disorders and drugs by (1) constructing a bioas-
say network for data in PubChem, visualizing complex
data in a network view and characterizing the network
using a variety of statistical tools, (2) mapping bioassay
targets into the human PPI networks, and investigating
the interrelationships between bioassay targets, and drug
targets, disease genes, and essential genes, and (3) quali-
tatively analyzing the potential of bioassay targets to be
potential therapeutic targets, quantitatively modeling
this potential, and confirming our results using literature
survey. Our analyses should provide some measures of
the value of the MLI data as a resource for both basic
chemical biology research and future therapeutic
discovery.
Results and discussion
We download all bioassay screening data from the Pub-
Chem BioAssay Database. As of January 2009, 1306
bioassays (1,126 with at least one active compound) and
more than 30 million compounds have been deposited
into PubChem by a variety of screening centers, and the
size of PubChem data keeps increasing continuously.
For each bioassay, tens to hundreds of thousand of com-
pounds are tested either against specific target proteins
in vitro or within a cell for investigating disease-related
mechanisms. There are totally 151,930 compounds that
are active in at least one bioassay, and 555,859 bioassay-
active compound pairs across all the bioassays. On aver-
age each active compound is active in 3.7 bioassays, and
each bioassay has 493.7 active compounds. Therefore a
very sparse bipartite network of bioassays and com-
pounds can be observed. In addition, 680 bioassays are
found associated with at least one target protein and are
considered target-based, and the rest are hence assumed
cell-based bioassays. Moreover, we have found 289 dis-
tinct protein GI (gene identifier) numbers for all target-
based bioassays, and 215 of them have official associated
gene symbols.
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Generating and characterizing the BioAssay Network
The complexity of PubChem data reveals that deep
investigation will be difficult without organizing and
visualizing the data in a rational matter, e.g., a bipartite
network of bioassays and compounds. We first extract a
small subnetwork from the complete bioassay-com-
pound network by limiting the degrees of bioassay
nodes and of compound nodes in the range of 20-40
and 10-20, respectively, resulting in a bipartite subnet-
work with 127 bioassays, 457 compounds, and 842 links
between them, as shown in Fig. 1a. There were a giant
cluster and a few big clusters, and each cluster is tended
to be composed of bioassays with the same purposes or
cellular components. To visualize PubChem bioassay
data with reasonable complexity, we generate a bioassay
network projection from the bipartite bioassay-com-
pound network as a complementary, bioassay-centered
view, where bioassays are nodes and two bioassays are
connected if they share similar binding profiles. We use
Jaccard coefficient (the fraction of active compounds
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Figure 1 The BioAssay network and topological distributions. The bioassay networks and topological distributions. (a) A small subnetwork
extracted from the complete bioassay-compound network. The size of each compound (bioassay) is proportional to the number of its active
bioassays (compounds), cell-based bioassays are colored according to their screening purposes, and target-based bioassays are colored
according to their cellular components. (b) The bioassay network in which nodes are bioassays and two bioassays are connected if they share at
least 10% active compounds. The size of each node is proportional to the number of its active compounds, and the coloring of nodes is similar.
(c) Distribution of the network node degrees. The power-law fitting clearly shows that is a typical scale-free network. (d) Distribution of the
average clustering coefficients. The almost constant fitting shows the bioassay network is not hierarchical, not as other biological networks.
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shared by two bioassays in the total number of distinct
active compounds of them) to measure the similarity of
bioassay binding profiles. By connecting any two bioas-
says that shared at least 10% active compounds, we gen-
erate a network of bioassays with 899 nodes and 6,080
edges as shown in Fig. 1b. Cell-based bioassays are
represented by circles and colored according their
screening purposes, while target-based bioassays are
represented by rectangles and colored by their cellular
components from the Gene Ontology database. From
Fig. 1b, we find that there do exist a few clusters that
contain both target-based and cell-based bioassays,
while most clusters in the network have nodes of the
same bioassay type (either target-based or cell-based).
According to the definition of an edge in this network,
such heterogeneous clusters reveal that the binding pro-
files of some target-based and some cell-based bioassays
are to some extent similar, which can be helpful on
understanding the protein-chemical interactions within
the cell-based bioassays and possibly identifying critical
proteins in the cell-based bioassays. Based on the bioas-
say network in Fig. 1b, we calculate the degree distribu-
tion P(k) of bioassays, measuring the probability of a
given bioassay connects with other k bioassays (Fig. 1c).
Excluding some outliers, the degree distribution
decreases slowly as the degree increases and follows a
power law with exponent = -1.009, and the fitting corre-
lation coefficient as 0.955 and R2 = 0.527. This is a typi-
cal scale-free network according to the definition by
Barabasi et al.[16], in which a small fraction of nodes
have most of the linked connected, and the majority of
nodes have only a few links, as observed in Fig. 1a. In
addition, we also compute the distributions of the aver-
age clustering coefficient (Fig. 1d), and find that it is
approximately independent on the node degree, and
fluctuated around the mean 0.78 (standard deviation
0.14) as the degree increased. This answers that our
bioassay network was scale-free, but not a hierarchical
network [17], although typical biological networks were
usually both scale-free and hierarchical. One reason
could be that the edges in the bioassay network have no
clear biological meaning.
BioAssay targets in human protein-protein interaction
network
The distributions of drug targets surrounding bioassay
targets are of importance to examine the global relation-
ships between them in the human PPI network, and to
gain understanding of the potential of bioassay targets
being promising new drug targets. We map bioassay tar-
gets and known drug targets into the UniHI network
[10,11], identify 228 and 1,339 entries for them, respec-
tively, and then calculate the median degree of each
bioassay target and each drug target in UniHI. We also
randomly select 347 human proteins from UniHI as a
reference set and calculate their median degrees. At
each degree k in the range of 1-51, we calculate the per-
centage of proteins with degrees >= k, and plot the
degree distributions of these three groups of proteins in
Fig. 2a. We discover that at each degree k there are
higher fractions of bioassay targets with degree >= k
than is the case for drug targets and random proteins.
Although it is difficult to speculate how a bias toward
high interaction targets might have emerged, this signifi-
cant difference in median degrees of bioassay targets
and known drug targets (P < 10–5, Wilcoxon rank-sum
test) has positive implications in that high degree pro-
teins are more likely to participate in multiple pathways,
and their modulation is thus likely to yield biochemical
implications of scientific interest. The high degree also
identifies targets as being somewhat distinct relative to
the current body of drug targets and thus may theoreti-
cally afford novel avenues for eventual therapeutics
development.
To gain better understanding of the biological func-
tions and the potential applications of these bioassays,
we need to map the original bioassay-compound bipar-
tite network into real biological networks, such as drug-
target network [2], human disease-gene network [15],
and human protein interactome [9]. As subsets of real
biological networks, these mapped networks can provide
important clues for identifying potential drug targets
with promising therapeutics to currently critical dis-
eases. We first investigate how bioassay targets distri-
bute around the essential genes. Picking an essential
gene in the UniHI network, we calculate the shortest
distances between it and other proteins. At each dis-
tance, we compute the fraction of bioassay targets in all
proteins with the same shortest distance to the picked
essential gene. We perform this shortest distance search
on all essential genes, and get the mean fraction of
bioassay targets over them at each distance. In addition,
to test the significance of the results, we randomly pick
a protein and repeat the same experiment for 10,000
times and obtain the mean fraction of bioassay targets
around the random protein at each shortest distance.
The results are shown in Fig. 2b, which shows that the
fractions of bioassay targets around essential genes are
significantly higher than the randomized expectation at
distance 1 and 2. At distance 1 from an essential gene,
on average 5.28% proteins are bioassay targets, compare
with the random expectation of 3.94% (P < 10–101). At
distance 2, the percentage of bioassay targets is 3.63%
and 3.17%(P < 10–44), respectively. These results confirm
that bioassay targets are more clustering around essen-
tial genes than regular proteins, which is a positive sign
for bioassay targets being potential drug targets accord-
ing to Yildrim et al.[2]. In addition, we also perform the
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same experiments to investigate the clustering of bioas-
say targets around drug targets (Fig. 2c) and disease
genes (Fig. 2d). Significant differences are observed
between the normal test and random control test (At
distance 1 from a bioassay target, P < 10–24 for drug tar-
gets and P < 10–12 for disease genes. At distance 2, P <
10–19 for drug targets and P < 10–27 for disease genes),
showing that bioassay targets are also statistically closer
to existing drug targets and disease genes than regular
proteins in UniHI, especially for drug targets.
Network models for BioAssay targets
The qualitative analysis above has answered “yes” to this
question: “Are the PubChem bioassays going on the
right track for identifying promising potential drug tar-
gets?” To gain more understanding on the potential of
bioassay targets being new drug targets quantitatively,
we develop a model to quantify the clustering of essen-
tial genes and drug targets surrounding them. First, by
computing the fraction fi of essential genes at each dis-
tance di, we obtain the distribution of bioassay targets
around essential genes, and then define the characteris-
tic distance Dc
e from an essential genes as follows:
1 2 1
2/ ( ) /D f dc
e n
i i= ∑ , where n is the diameter of the
network. The characteristic distance Dc
e of an essential
bioassay target will be less than 1.0, and that of non-
essential bioassay targets will be close to or greater than
1.0. The mechanism underlying this formula is from the
Coulomb law in electrostatics. We can view each “essen-
tial gene” as a unit charge that generated an electric
field with field strength f di i/
2 , and all these electric
fields accumulate at the position of the picked bioassay
target. We rank bioassay targets based on their Dc
e
values, and the ranking quantifies the distance between
a bioassay target and the essential genes surrounding it.
The characteristic distance Dc
d between bioassay tar-
gets and drug targets can be calculated with the same
formula. We then rank the characteristic distance Dc
e of
the remaining bioassay targets in the ascending order,
and discretize Dc
e with bin size of 0.5 (e.g., [1.0,1.5),
[1.5,2.0), …). Within each bin, bioassay targets are
ranked by the descending order of the Dc
d values since
we expect to find diverse new drug targets with longer
distance from existing drug targets. Finally, bioassay tar-
gets with small degrees in the UniHI network are
excluded. According to this paradigm, the top 10 poten-
tial drug targets with Dc
d < 2 0. , Dc
d < 3 0. and at least
17 interacting proteins are listed in Table 1. Literature
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Figure 2 Characteristics of BioAssay targets. Characteristics of the bioassay network, including the degree distributions of bioassay targets,
drug targets, and random proteins (a), followed by the distributions of the fractions of bioassay targets around (b) essential genes, (c)
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survey confirmed that 7 of the top 10 bioassay targets
are promising drug targets under investigation. The
results demonstrate the correlation between the poten-
tial of bioassay targets as new drug targets and how
close they are to essential genes and existing drug
targets in the human PPI network.
Conclusions
In this work we integrate PubChem bioassay data and
other biological databases such as DrugBank and UniHI,
and systematically analyze them to address these ques-
tions: 1) Are the present bioassays going on the right
track for identifying new drug targets? 2) What are the
relationships between bioassay targets and existing drug
targets in the context of human protein interactome? 3)
How to quantify the potential of bioassay targets being
new drug targets? In addition to the basic science objec-
tive of producing chemical probes for studying the func-
tions of genes, cells, and biochemical pathways at a
molecular level, an original mandate of the MLI pro-
gram has been to provide an informational basis to sup-
port drug discovery in service of important biomedical
objectives [7]. Although not directly aligned with cur-
rent MLI mandates, these questions may prove useful in
gauging MLI progress as a cradle for fostering chemical
biology research breakthroughs and future therapeutics
discovery.
In this work, we first construct a bioassay network,
and use network topology analysis to demonstrate that
this is a scale-free network but is not hierarchical, which
is different from typical biological networks that are
usually both scale-free and hierarchical. Some cell-based
bioassays share a large portion of active compounds
with target-based bioassays, which is helpful to deter-
mine the interacting proteins in the cells. We map
bioassay targets into the human PPI network called
UniHI and find they are significantly clustering around
drug targets and essential genes than randomized expec-
tation. Hence current bioassay screenings were on the
right track for identifying potential drug targets. We
observe that the median degree of bioassay targets is
significantly higher than not only the UniHI network
median degree, but also the median degree of approved
drug targets. More importantly, our network analysis
also reveal that bioassay targets are much more likely to
have direct physical PPIs with established drug targets
than is the case for randomly selected genes within the
UniHI network. This critical finding should trigger
the attention of the community for reconsidering the
selection of bioassay targets in a more rational matter.
Finally, we propose a model to quantitatively prioritize
the potential of bioassay targets as new drug targets,
and conduct literature survey for confirming our predic-
tions with reasonable accuracy. These observations
could shed bright insights to future therapeutic
discovery.
In conclusion, this paper represents an attempt to
objectively assess the MLI progress to date as a tool for
the chemical biology and pharmaceutical communities,
by probing the relative novelty of target selection, the
likelihood that these targets will prove interesting from
a chemical biology or a potential therapeutic perspec-
tive. Significant distributional differences between bioas-
say targets and known drug targets speaks well of a
basic science program introducing new insight into the
field of chemical biology.
Methods
Data sources
We obtain the chemical structures of all approved drug
compounds and the gene symbols of their target pro-
teins from the DrugBank database [12,13]. As of January
22, 2009, there are 1,493 FDA-approved drugs, more
than 800 human proteins, and the drug-drug target
associations. Data of human disease genes are down-
loaded from the OMIM database [14]. The resulting
bipartite human disease network consisting of 1,284
distinct diseases, 1,777 disease genes, and 2,929 disease-
gene associations. In addition, human PPI data are
obtained from UniHI, a unified human PPI network
containing over 250,000 human PPIs collected from
14 major PPI sources, including high-quality systematic
interactome mapping and literature curation.
Mouse phenotype and human essential genes
A human gene is defined as “essential” if a knockout of
its mouse ortholog confers lethality. To find human
essential genes, we first extract mouse essential genes
from the Mouse Genome Informatics Database [18], and
through the human-mouse ortholog associations we
obtain human essential genes, which correspond to
2,564 entries in UniHI. We obtain the official gene
Table 1 Summary of the calculation results for the top
10 predictions of bioassay targets and the literature that
confirm them as potential drug targets.
Gene Symbol Dc
e Dc
d Degree Literature Evidence
SULT1E1 1.4744 5.1837 17 Confirmed [19]
WEE1 1.3499 3.1641 47 Confirmed [20]
RGS7 1.3440 3.0462 20 Confirmed [21,22]
SMN2 1.6241 5.8903 28 Confirmed [23]
RNGTT 1.7738 4.2353 100 Not yet
STK16 1.6785 3.9232 34 Not yet
PAK7 1.7091 3.8467 30 Confirmed [24]
NEK2 1.7952 3.5328 47 Confirmed [25]
YWHAG 1.8603 3.3451 339 Not yet
MAPK10 1.6685 3.0371 27 Confirmed [26]
drug targets, and (d) disease genes at each shortest distance in the human
PPI network, compared with the corresponding randomized expectation.
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symbol of each bioassay target from its GI number, and
find 228 entries among the total 21,051 human proteins
in UniHI.
Network and topological analysis
A network is an undirected graph consisting of some
nodes and edges connecting nodes. A node can repre-
sent any object, and an edge connects two nodes and
usually carries some physical meaning such as interac-
tion, similarity, and etc. The “degree” of a node is the
number of edges connecting it to other nodes. Given a
node degree i, we count the number of nodes with
degree i in the network (i = 1, 2, …), and then normal-
ize these counts to obtain the node degree distribution.
The clustering coefficient Ci of a network is defined as
Ci = 2n/[ki * (ki – 1)], where n denotes the number of
direct neighbors of a given node i, and ki is the number
of links among the n neighbors of node i. If the cluster-
ing coefficient of a node equals 1, the node is at the
center of a fully connected cluster called a clique. If the
clustering coefficient is close to 0, the node is in a
loosely connected region. We calculate average cluster-
ing coefficient over nodes with the same degree, and
then obtain the distribution of average clustering coeffi-
cient over node degrees. The average of Ci over all
nodes of a network assesses network modularity. In this
paper, the layouts of the projected bioassay network are
obtained using free software called Cytoscape 2.6.2, and
its free plug-in named Network Analyzer is used to
compute all the network topological parameters and
distributions.
Statistical tests
Wilcoxon rank-sum test is used to test if the medians of
two sample vectors are equal, and returns the probabil-
ity P of the positive answer at a given significance level
(it is 0.05 in all tests performed in this paper). We call
the “ranksum” function in the MATLAB software to
conduct all Wilcoxon rank-sum tests.
Methods
Data sources
We obtain the chemical structures of all approved drug
compounds and the gene symbols of their target pro-
teins from the DrugBank database [12,13]. As of January
22, 2009, there are 1,493 FDA-approved drugs, more
than 800 human proteins, and the drug-drug target
associations. Data of human disease genes are down-
loaded from the OMIM database [14]. The resulting
bipartite human disease network consisting of 1,284 dis-
tinct diseases, 1,777 disease genes, and 2,929 disease-
gene associations. In addition, human PPI data are
obtained from UniHI, a unified human PPI network
containing over 250,000 human PPIs collected from
14 major PPI sources, including high-quality systematic
interactome mapping and literature curation.
Mouse phenotype and human essential genes
A human gene is defined as “essential” if a knockout of
its mouse ortholog confers lethality. To find human
essential genes, we first extract mouse essential genes
from the Mouse Genome Informatics Database [18], and
through the human-mouse ortholog associations we
obtain human essential genes, which correspond to
2,564 entries in UniHI. We obtain the official gene sym-
bol of each bioassay target from its GI number, and find
228 entries among the total 21,051 human proteins in
UniHI.
Network and topological analysis
A network is an undirected graph consisting of some
nodes and edges connecting nodes. A node can represent
any object, and an edge connects two nodes and usually
carries some physical meaning such as interaction, simi-
larity, and etc. The “degree” of a node is the number of
edges connecting it to other nodes. Given a node degree
i, we count the number of nodes with degree i in the net-
work (i = 1, 2, …), and then normalize these counts to
obtain the node degree distribution. The clustering coeffi-
cient Ci of a network is defined as Ci = 2n/[ki * (ki – 1)],
where n denotes the number of direct neighbors of a
given node i, and ki is the number of links among the n
neighbors of node i. If the clustering coefficient of a node
equals 1, the node is at the center of a fully connected
cluster called a clique. If the clustering coefficient is close
to 0, the node is in a loosely connected region. We calcu-
late average clustering coefficient over nodes with the
same degree, and then obtain the distribution of average
clustering coefficient over node degrees. The average of
Ci over all nodes of a network assesses network modular-
ity. In this paper, the layouts of the projected bioassay
network are obtained using free software called Cytoscape
2.6.2, and its free plug-in named Network Analyzer is
used to compute all the network topological parameters
and distributions.
Statistical tests
Wilcoxon rank-sum test is used to test if the medians of
two sample vectors are equal, and returns the probabil-
ity P of the positive answer at a given significance level
(it is 0.05 in all tests performed in this paper). We call
the “ranksum” function in the MATLAB software to
conduct all Wilcoxon rank-sum tests.
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